Skip to content

Xencor Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: November 4, 2026 results vs estimates

Xencor Inc · E.XNCR.NASDAQ · United States
Use symbol E.XNCR.NASDAQ in our API & Excel add-in to retrieve this data ↓
29.21
(-0.03%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 75.45%

Xencor Inc Forecast

Xencor Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 75.4% a year, a typical one-standard-deviation range is 26.11–32.31 over a week, 22.85–35.57 over a month and 7.1725–51.25 over a year. (Signals as of 1 Nov 2026.)

Xencor Inc Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
Xencor Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Xencor Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Xencor Inc
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Xencor Inc
P/S
11.42x
Mid-range vs own history
QoQ −43.2%
YoY +61.8%
now 11.41535.07 low21.55 high
ⓘP/S As of 22 Nov 2026.See Xencor Inc returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Xencor Inc
P/B
4.08x
Stretched vs own history
QoQ −2.6%
YoY +116.2%
now 4.08381.32 low5.19 high
ⓘP/B As of 22 Nov 2026.See Xencor Inc returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Xencor Inc
EV/Sales
10.19x
Mid-range vs own history
QoQ −37.7%
YoY +87.0%
now 10.1943.47 low17.82 high
ⓘEV/Sales As of 22 Nov 2026.See Xencor Inc returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Xencor Inc
FCF Yield
-7.7%
Mid-range vs own history
QoQ −21.9%
YoY −36.6%
now -7.7095-22.37 low-6.07 high
ⓘFCF Yield As of 22 Nov 2026.See Xencor Inc returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Xencor Inc
Earnings Yield
-5.1%
Mid-range vs own history
QoQ −33.5%
YoY −56.2%
now -5.1498-20.42 low-4.06 high
ⓘEarnings Yield As of 22 Nov 2026.See Xencor Inc returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Xencor Inc
Market Cap
$2.3B
Highest in 5 years
QoQ +8.5%
YoY +93.8%
now 2288.6911840.39 low2,906 high
ⓘMarket Cap As of 22 Nov 2026.See Xencor Inc returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Xencor Inc
Net Debt
-$245M
High vs own history
QoQ −37.4%
YoY −8.9%
now -244.852-391.24 low-244.85 high
ⓘNet Debt As of 22 Nov 2026.See Xencor Inc returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Xencor Inc
Current Ratio
6.54x
Mid-range vs own history
QoQ +2.3%
YoY +9.1%
now 6.53845.99 low6.57 high
ⓘCurrent Ratio As of 22 Nov 2026.See Xencor Inc returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Xencor Inc
Quick Ratio
6.54x
Mid-range vs own history
QoQ +2.3%
YoY +9.1%
now 6.53845.99 low6.57 high
ⓘQuick Ratio As of 22 Nov 2026.See Xencor Inc returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Xencor Inc
Interest Coverage
-3.91x
Mid-range vs own history
QoQ −20.8%
YoY +188.0%
now -3.9133-5.08 low-1.36 high
ⓘInterest Coverage As of 22 Nov 2026.See Xencor Inc returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Xencor Inc
Debt / Equity
0.29x
Mid-range vs own history
QoQ +120.6%
YoY −11.7%
now 0.28590.13 low0.34 high
ⓘDebt / Equity As of 22 Nov 2026.See Xencor Inc returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Xencor Inc
Piotroski F-Score
5
Mid-range vs own history
QoQ +150.0%
YoY +66.7%
now 52 low5 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Xencor Inc returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Xencor Inc
Altman Z-Score
5.41
Mid-range vs own history
QoQ +30.6%
YoY +154.7%
now 5.41250.7 low7.18 high
ⓘAltman Z-Score As of 22 Nov 2026.See Xencor Inc returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  18 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  19 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Xencor Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Xencor Inc fundamentals: income statement, balance sheet & cash flow

Xencor Inc reported revenue of $125.6m and net income of -$91.9m in FY2025, the year ended 31 December 2025 — revenue up 13.7% and net income up 60.5% on the prior year. Free cash flow was -$138.3m. These figures are as reported in the filings, not restated: 15 fiscal years and 57 quarters of history, back to December 2011. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$125.6m
+13.7%
Net income
-$91.9m
+60.5%
Gross margin
91.63%
Free cash flow
-$138.3m
+33.6%
Net debt
$133.7m
Shares short (30 Oct 2026)
12.90m
6.58 days to cover
Xencor Inc income statement, annual, as reported · USD millions unless stated
USD millionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue125.6110.5168.3164.6275.1
Cost of revenue10.5227.7253.68.87.5
Gross profit115.1-117.2-85.3164.6275.1
Research & development239.4227.7253.6199.6192.5
Selling, general & admin.———47.538.8
Operating income-177.5-178.4-138.6-82.543.8
EBITDA-47.0-186.2-125.9-73.751.3
Interest expense31.936.66.236.87.5
Pre-tax income-89.4-234.9-120.4-54.582.6
Income tax2.51.65.80.7-7.5
Net income-91.9-232.6-126.1-55.282.6

Download Xencor Inc fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.XNCR.NASDAQ&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 15 fiscal years and 57 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Xencor Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Xencor Inc Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Xencor Inc; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Xencor Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Xencor Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Xencor Inc (United States)

Xencor Inc is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

Frequently asked questions

What is Xencor Inc?
Xencor Inc is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Xencor Inc price?
The latest close is 29.21 (1 Nov 2026), -0.03% on the day. The price at the top of the page refreshes during the trading day.
Is Xencor Inc in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Xencor Inc?
20-day realised volatility is 75.4% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 21.8% over a month and 10.6% over a week.
What factors affect Xencor Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Xencor Inc, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Xencor Inc?
58 backtested tactical asset allocation strategies trade Xencor Inc through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Xencor Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of Xencor Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Xencor Inc historical data?
In the Free historical data section of this page: the last 10 years of Xencor Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Xencor Inc historical data (last 10 years)

Browse or instantly download the last 10 years of Xencor Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.XNCR.NASDAQ&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-2033.26
2026-11-1934.01
2026-11-1834.39
2026-11-1734.5
2026-11-1635.4
2026-11-1337.09
2026-11-1238.13
2026-11-1139.97
2026-11-1039.39
2026-11-0938.59
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.